Related Experiment Video
Updated: Aug 8, 2026
A Three-dimensional Model of Spheroids to Study Colon Cancer Stem Cells
Published on: January 22, 2021
Staurosporine increases carcinoembryonic antigen expression in a human colon cancer cell line
1Department of Neuroscience, Section of Pharmacology and Medical Oncology, University of Rome Tor Vergata, Italy. Angelo.Aquino@UniRoma2.it
Abstract:
Staurosporine (ST), a protein kinase C inhibitor, was found to produce antitumor effects against C22.20, a clonal subline derived from colon cancer HT-29 line, selected for low expression of carcinoembryonic antigen (CEA). However, as assessed by FACS analysis using propidium iodide, no apoptosis or cell cycle alteration was found on day 3 after treatment of C22.20 cells with ST (1-100nM). Exposure of cells to graded concentrations of the drug (i.e., from 1 to 25nM) resulted in a concentration-dependent increase in the percentage of CEA positive cells, as determined by flow cytometric analysis. However, when higher concentrations (i.e. 50nM - 100nM) of ST were used, the percentage of CEA positive cells declined compared to that detected in 25nM-treated tumor. Since these results were obtained in a clonal cell population, it is reasonable to hypothesize that induction rather than selection mechanism is involved in this phenomenon. The potential clinical interest of the present findings stems from the consideration that treatment with ST or its derivatives could improve sensitivity and efficacy of diagnostic and/or immunotherapeutic approaches based on CEA molecules.
Insights
Staurosporine (ST) showed antitumor effects on colon cancer cells. It increased carcinoembryonic antigen (CEA) expression at lower doses, suggesting potential for improved cancer diagnostics and immunotherapy.
Area of Science:
- Oncology
- Pharmacology
- Cancer Biology
Background:
- Staurosporine (ST) is a protein kinase C inhibitor with demonstrated antitumor properties.
- Colon cancer cell line HT-29 subline C22.20 exhibits low carcinoembryonic antigen (CEA) expression.
- CEA is a significant biomarker in colorectal cancer diagnostics and therapeutics.
Purpose of the Study:
- To investigate the effect of Staurosporine (ST) on the antitumor activity and CEA expression in a colon cancer cell line.
- To explore the potential of ST in enhancing the efficacy of CEA-based diagnostic and immunotherapeutic strategies.
Main Methods:
- C22.20 colon cancer cells were treated with varying concentrations of Staurosporine (ST).
- Flow cytometry was used to assess cell cycle, apoptosis (propidium iodide staining), and CEA expression.
- FACS analysis quantified CEA-positive cells following ST treatment.
Main Results:
- Staurosporine (ST) treatment did not induce apoptosis or cell cycle alterations in C22.20 cells at concentrations up to 100nM.
- A concentration-dependent increase in CEA-positive cells was observed with ST concentrations from 1nM to 25nM.
- Higher ST concentrations (50nM-100nM) led to a decrease in CEA-positive cells compared to the 25nM group.
- The observed changes in CEA expression are hypothesized to result from an induction mechanism rather than cell selection.
Conclusions:
- Staurosporine (ST) influences CEA expression in colon cancer cells.
- The modulation of CEA by ST suggests potential for enhancing the sensitivity and effectiveness of CEA-targeted cancer diagnostics and immunotherapies.
- Further research into ST derivatives may offer improved clinical strategies for colorectal cancer management.
Related Concept Videos
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:25Mutagenicity and Carcinogenicity